Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study Oral Contraceptives and the Risk of Ischemic Stroke
Background and Purpose — Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contrace...
Saved in:
Published in | Stroke (1970) Vol. 33; no. 5; pp. 1202 - 1208 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
01.05.2002
American Heart Association, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0039-2499 1524-4628 1524-4628 |
DOI | 10.1161/01.STR.0000015345.61324.3F |
Cover
Abstract | Background and Purpose
—
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.
Methods
—
A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.
Results
—
Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).
Conclusions
—
Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel). |
---|---|
AbstractList | Background and Purpose
—
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.
Methods
—
A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.
Results
—
Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).
Conclusions
—
Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel). Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.BACKGROUND AND PURPOSEEpidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives.A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.METHODSA multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors.Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).RESULTSTwo hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8).Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel).CONCLUSIONSThird-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel). BACKGROUND AND PURPOSE: Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. METHODS: A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. RESULTS: Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). CONCLUSIONS: Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel). Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the progestogens desogestrel or gestodene. This study assesses the risk of ischemic stroke with several types of oral contraceptives. A multicenter, population-based, case-control study was performed in 9 Dutch centers in women aged 18 to 49 years. Women with a first ischemic stroke were compared with control women without vascular diseases. The control subjects were recruited by random-digit dialing and were stratified by age, area of residence, and year of stroke. All patients and control subjects filled in a questionnaire about the use of oral contraceptives and risk factors for ischemic stroke. Odds ratios were adjusted for the stratification factors. Two hundred three women with an ischemic stroke and 925 control women were included. The risk of stroke in women using any type of oral contraceptives versus none was 2.3 (95% CI 1.6 to 3.3). Current users of first-generation oral contraceptives had an odds ratio of 1.7 (95% CI 0.7 to 4.4). Low-dose second-generation oral contraceptives increased the risk of stroke 2.4 times (95% CI 1.6 to 3.7), and third-generation oral contraceptives increased the risk of stroke 2.0 times (95% CI 1.2 to 3.5). The risk of stroke in women using third-generation oral contraceptives was not different from that in women using second-generation oral contraceptives (odds ratio 1.0, 95% CI 0.6 to 1.8). Third-generation oral contraceptives (containing desogestrel or gestodene) confer the same risk of first ischemic stroke as second-generation oral contraceptives (containing levonorgestrel). |
Author | van den Bosch, Maurice A.A.J. Kemmeren, Jeanet M. Helmerhorst, Frans M. Bollen, Edward L.E.M. van der Graaf, Yolanda Tanis, Bea C. Algra, Ale Rosendaal, Frits R. |
Author_xml | – sequence: 1 givenname: Jeanet M. surname: Kemmeren fullname: Kemmeren, Jeanet M. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 2 givenname: Bea C. surname: Tanis fullname: Tanis, Bea C. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 3 givenname: Maurice A.A.J. surname: van den Bosch fullname: van den Bosch, Maurice A.A.J. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 4 givenname: Edward L.E.M. surname: Bollen fullname: Bollen, Edward L.E.M. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 5 givenname: Frans M. surname: Helmerhorst fullname: Helmerhorst, Frans M. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 6 givenname: Yolanda surname: van der Graaf fullname: van der Graaf, Yolanda organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 7 givenname: Frits R. surname: Rosendaal fullname: Rosendaal, Frits R. organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands – sequence: 8 givenname: Ale surname: Algra fullname: Algra, Ale organization: From the Julius Centre for Patient Oriented Research (J.M.K., M.A.A.J.v.d.B., Y.v.d.G., A.A.) and the Department of Neurology (A.A.), University Medical Centre Utrecht, Utrecht, the Netherlands, and the Department of Haematology (B.C.T.), Department of Neurology (E.E.L.M.B.), Department of Obstetrics, Gynecology and Reproductive Medicine (F.M.H.), and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Centre, Leiden, the Netherlands |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13659553$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11988591$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0U9rFDEYBvAgFbutfgUZCko9zJg3_zbpyWXpamFhYbueQyaTwdTZyZpkhH5703a10Iu55JBfnoT3OUMnYxgdQheAGwABnzE0t7ttgx8WcMp4I4AS1tDVKzQDTljNBJEnaIYxVTVhSp2is5TuCidU8jfoFEBJyRXM0Hrr088q9NUiZhe9Gardjxj2bUg-VX6stm4w2YexyqHaxHK8DGOOxrpD9r9dqi63i93N5lN1m6fu_i163ZshuXfH_Rx9X13vlt_q9ebrzXKxri1lONdWWNYRB1gI0rdYEkZa4F1nQTDFmJsLK2nXgbK4BSt5zwEr5VrLqeyI7ek5-viUe4jh1-RS1nufrBsGM7owJT0vQZQrUuDFC3gXpjiWv2lQc0mlpKqg90c0tXvX6UP0exPv9d8hFfDhCEyyZuijGa1Pz44KrjinxX15cjaGlKLrtfX5cXplYn7QgPVDfxqDLv3p5_70Y3-arkrE1YuIf6_8__If8smdDQ |
CODEN | SJCCA7 |
CitedBy_id | crossref_primary_10_1016_j_thromres_2003_10_019 crossref_primary_10_1097_NRL_0000000000000226 crossref_primary_10_1016_j_contraception_2008_07_024 crossref_primary_10_2217_17455057_1_1_133 crossref_primary_10_1186_s12872_019_1040_4 crossref_primary_10_15585_mmwr_rr7304a1 crossref_primary_10_1097_01_AOG_0000172428_78411_b0 crossref_primary_10_1017_S0317167100003620 crossref_primary_10_3109_13625187_2014_960561 crossref_primary_10_1016_j_lpm_2011_02_035 crossref_primary_10_1111_j_1743_6109_2012_02876_x crossref_primary_10_1007_s00404_016_4143_5 crossref_primary_10_1111_head_12035 crossref_primary_10_1111_j_1538_7836_2005_01690_x crossref_primary_10_3389_fneur_2019_00993 crossref_primary_10_1002_14651858_CD011054_pub2 crossref_primary_10_1212_CON_0000000000001237 crossref_primary_10_1210_en_2018_00465 crossref_primary_10_1111_acem_13243 crossref_primary_10_1177_1076029612440036 crossref_primary_10_1016_j_maturitas_2016_02_008 crossref_primary_10_1016_j_atherosclerosis_2012_04_024 crossref_primary_10_1016_j_maturitas_2011_12_010 crossref_primary_10_15585_mmwr_mm6618a5 crossref_primary_10_1007_s00404_011_2190_5 crossref_primary_10_1046_j_1538_7836_2003_00162_x crossref_primary_10_1111_bjh_14043 crossref_primary_10_1182_asheducation_V2005_1_1_1 crossref_primary_10_1046_j_1538_7836_2003_00264_x crossref_primary_10_1007_s11886_013_0374_2 crossref_primary_10_1016_S0741_5214_02_75465_7 crossref_primary_10_2217_fnl_09_66 crossref_primary_10_1016_j_reuma_2009_01_012 crossref_primary_10_1016_j_rdc_2016_12_001 crossref_primary_10_1182_blood_2011_12_395889 crossref_primary_10_1212_01_CON_0000300025_15285_92 crossref_primary_10_1111_j_1365_2141_2011_08935_x crossref_primary_10_1097_00008571_200310000_00002 crossref_primary_10_1056_NEJMcp030751 crossref_primary_10_1016_j_fertnstert_2009_08_052 crossref_primary_10_1038_ncprheum0484 crossref_primary_10_1016_j_ajog_2005_12_045 crossref_primary_10_1016_j_clindermatol_2009_03_006 crossref_primary_10_20473_imhsj_v3i1_2019_37_50 crossref_primary_10_2165_00023210_200620020_00004 crossref_primary_10_1016_j_contraception_2005_08_005 crossref_primary_10_1016_j_thromres_2015_04_021 crossref_primary_10_1517_17455057_1_1_133 crossref_primary_10_1016_j_ijoa_2007_10_005 crossref_primary_10_1177_1756286420985237 crossref_primary_10_1016_j_jaut_2011_11_002 crossref_primary_10_1016_j_beem_2012_11_003 crossref_primary_10_1111_j_1538_7836_2012_04927_x crossref_primary_10_1016_S1634_7072_16_80383_9 crossref_primary_10_1007_s11055_018_0610_8 crossref_primary_10_1016_j_thromres_2015_04_013 crossref_primary_10_1002_pds_663 crossref_primary_10_1097_01_PGO_0000316647_92408_1b crossref_primary_10_1097_FPC_0b013e328338f54f crossref_primary_10_1089_152460902760277921 crossref_primary_10_22270_jddt_v10i6_s_4494 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_107624 crossref_primary_10_1016_j_fertnstert_2006_08_012 crossref_primary_10_1016_S1474_4422_09_70239_X crossref_primary_10_1007_s11883_010_0118_3 crossref_primary_10_17116_jnevro20171171270_74 crossref_primary_10_1177_1591019918782964 crossref_primary_10_1016_j_fertnstert_2004_07_935 crossref_primary_10_1016_S1701_2163_16_30260_2 crossref_primary_10_1177_875512251102700504 crossref_primary_10_1182_blood_2007_08_110254 crossref_primary_10_1186_s12905_021_01305_5 crossref_primary_10_2217_17455057_3_3_369 crossref_primary_10_1111_j_1526_4610_2011_02051_x crossref_primary_10_1016_j_osfp_2011_03_001 crossref_primary_10_1016_S0377_1237_08_80021_4 crossref_primary_10_1080_15265161_2014_919364 crossref_primary_10_1097_GCO_0b013e32821642e6 crossref_primary_10_1182_blood_2011_09_380618 crossref_primary_10_1007_s11239_014_1077_2 crossref_primary_10_1111_jth_14307 crossref_primary_10_1186_1471_2261_6_40 crossref_primary_10_1556_OH_2011_29201 crossref_primary_10_1038_clpt_2009_29 crossref_primary_10_1016_j_mayocp_2020_08_045 crossref_primary_10_1007_s11940_018_0492_7 crossref_primary_10_1177_1358863X16668263 crossref_primary_10_1097_NRL_0b013e318191f600 crossref_primary_10_1111_j_1538_7836_2008_03266_x crossref_primary_10_1590_0034_7167_2016_0056 crossref_primary_10_1016_S1957_2557_08_74040_9 crossref_primary_10_1002_jcph_637 crossref_primary_10_1177_147470491301100315 crossref_primary_10_3724_SP_J_1008_2011_01282 crossref_primary_10_1111_jth_12531 crossref_primary_10_1007_s11239_007_0180_z crossref_primary_10_1111_1471_0528_14358 crossref_primary_10_1111_jth_13109 crossref_primary_10_1111_head_13796 crossref_primary_10_1007_s15202_015_0641_8 crossref_primary_10_1016_j_fertnstert_2004_03_019 crossref_primary_10_1016_S1701_2163_16_30261_4 crossref_primary_10_1080_14787210_2020_1757430 crossref_primary_10_1007_s11940_008_0049_2 crossref_primary_10_1016_j_contraception_2016_05_014 crossref_primary_10_1111_ejh_14061 crossref_primary_10_1182_asheducation_2005_1_1 crossref_primary_10_1016_j_fertnstert_2008_08_093 crossref_primary_10_1016_j_medcli_2010_05_020 crossref_primary_10_1783_147118907781004750 crossref_primary_10_1007_s11926_021_01006_w crossref_primary_10_1136_bcr_2012_008055 crossref_primary_10_1111_j_1538_7836_2005_01442_x crossref_primary_10_1016_j_jns_2003_08_012 crossref_primary_10_1016_S0246_0378_06_38887_2 crossref_primary_10_1016_j_expneurol_2014_02_011 crossref_primary_10_1016_S1474_4422_05_70220_9 crossref_primary_10_1016_j_contraception_2012_09_023 crossref_primary_10_1016_j_mcna_2015_01_007 crossref_primary_10_1016_j_jaad_2007_12_040 crossref_primary_10_1136_bmjsrh_2019_OOC crossref_primary_10_25692_ACEN_2019_3_2 crossref_primary_10_1016_j_ncl_2008_05_009 crossref_primary_10_1177_0024363918813579 crossref_primary_10_1586_17474108_3_2_189 crossref_primary_10_1093_humupd_dml028 crossref_primary_10_4103_0022_3859_147036 crossref_primary_10_1530_EJE_13_0493 crossref_primary_10_1007_s10227_004_0755_7 crossref_primary_10_1007_s11154_011_9178_0 crossref_primary_10_1016_S2173_5743_10_70008_3 crossref_primary_10_2165_00023210_200519080_00004 crossref_primary_10_1016_j_ando_2009_12_001 crossref_primary_10_1016_j_ando_2009_12_002 crossref_primary_10_1097_MBC_0b013e32833b2b84 crossref_primary_10_1111_jth_13045 crossref_primary_10_1016_S0246_1064_09_46119_X crossref_primary_10_1111_j_1365_2141_2009_07805_x |
Cites_doi | 10.1111/j.1471-0528.1994.tb13578.x 10.1016/S0010-7824(97)00204-7 10.7326/0003-4819-72-1-111 10.1093/oxfordjournals.aje.a114869 10.1136/bmj.2.5965.241 10.7326/0003-4819-127-8_Part_1-199710150-00003 10.1016/S0010-7824(98)00032-8 10.1056/NEJMoa003216 10.1016/0010-7824(94)90106-6 10.1001/jama.1975.03240190022010 10.1016/S0140-6736(95)91929-5 10.1111/j.1471-0528.1998.tb10235.x 10.1016/S0140-6736(95)12393-8 10.7326/0003-4819-89-1-58 10.1001/archneur.1995.00540280029015 10.1093/oxfordjournals.aje.a113955 10.1093/oxfordjournals.aje.a116946 10.1016/S0140-6736(99)01013-2 10.1056/NEJM199607043350102 10.1182/blood.V89.8.2817 10.1161/str.26.3.361 10.1136/bmj.312.7023.83 10.1016/S0140-6736(95)91928-7 10.1016/S0140-6736(95)91926-0 |
ContentType | Journal Article |
Copyright | 2002 INIST-CNRS Copyright American Heart Association, Inc. May 2002 |
Copyright_xml | – notice: 2002 INIST-CNRS – notice: Copyright American Heart Association, Inc. May 2002 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
DOI | 10.1161/01.STR.0000015345.61324.3F |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) ProQuest Nursing and Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4628 |
EndPage | 1208 |
ExternalDocumentID | 124797781 11988591 13659553 10_1161_01_STR_0000015345_61324_3F |
Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GeographicLocations | Netherlands Europe |
GeographicLocations_xml | – name: Netherlands |
GroupedDBID | --- .3C .55 .GJ .XZ .Z2 01R 0R~ 123 1J1 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 71W 77Y 7O~ A9M AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAUEB AAXQO AAYEP AAYJJ AAYXX ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACCJW ACDDN ACDOF ACEWG ACGFS ACGOD ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADGHP ADHPY ADNKB AE3 AE6 AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BCGUY BOYCO BQLVK BS7 C45 CITATION CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B M18 N4W N9A N~7 N~B N~M O9- OAG OAH OB3 OCUKA ODA ODMTH OGROG OHYEH OK1 OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M W8F WH7 WOQ WOW X3V X3W X7M XXN XYM YFH YHZ YQJ YYP ZB8 ZGI ZZMQN IQODW ACIJW AWKKM CGR CUY CVF ECM EIF NPM OJAPA OLW RHF YCJ K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c340t-c6c4d2e10662fb08242b15ddc164944e76c83dd19c0b1c85f51099ebc538d2cf3 |
ISSN | 0039-2499 1524-4628 |
IngestDate | Fri Jul 11 12:04:54 EDT 2025 Mon Jun 30 03:18:38 EDT 2025 Wed Feb 19 02:36:03 EST 2025 Mon Jul 21 09:11:27 EDT 2025 Tue Jul 01 01:13:40 EDT 2025 Thu Apr 24 22:56:23 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Human Nervous system diseases Oral administration Cardiovascular disease Route of administration Epidemiology Thrombosis Artery Cerebral disorder Arterial disease Vascular disease Ischemia Central nervous system disease Risk factor Contraceptive Cerebrovascular disease Brain (vertebrata) |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c340t-c6c4d2e10662fb08242b15ddc164944e76c83dd19c0b1c85f51099ebc538d2cf3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 11988591 |
PQID | 197838839 |
PQPubID | 35232 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_71643592 proquest_journals_197838839 pubmed_primary_11988591 pascalfrancis_primary_13659553 crossref_citationtrail_10_1161_01_STR_0000015345_61324_3F crossref_primary_10_1161_01_STR_0000015345_61324_3F |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2002-05-01 |
PublicationDateYYYYMMDD | 2002-05-01 |
PublicationDate_xml | – month: 05 year: 2002 text: 2002-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States – name: Hagerstown |
PublicationTitle | Stroke (1970) |
PublicationTitleAlternate | Stroke |
PublicationYear | 2002 |
Publisher | Lippincott Williams & Wilkins American Heart Association, Inc |
Publisher_xml | – name: Lippincott Williams & Wilkins – name: American Heart Association, Inc |
References | (e_1_3_3_6_2) 1963; 1 (e_1_3_3_7_2) 1961; 2 e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 (e_1_3_3_15_2) 1998; 351 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_14_2 e_1_3_3_11_2 e_1_3_3_10_2 (e_1_3_3_2_2) 1962; 2 e_1_3_3_5_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_20_2 e_1_3_3_1_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 (e_1_3_3_8_2) 1993; 81 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_9_2 doi: 10.1111/j.1471-0528.1994.tb13578.x – ident: e_1_3_3_17_2 doi: 10.1016/S0010-7824(97)00204-7 – ident: e_1_3_3_3_2 doi: 10.7326/0003-4819-72-1-111 – ident: e_1_3_3_23_2 doi: 10.1093/oxfordjournals.aje.a114869 – ident: e_1_3_3_24_2 doi: 10.1136/bmj.2.5965.241 – ident: e_1_3_3_29_2 doi: 10.7326/0003-4819-127-8_Part_1-199710150-00003 – ident: e_1_3_3_18_2 doi: 10.1016/S0010-7824(98)00032-8 – ident: e_1_3_3_20_2 doi: 10.1056/NEJMoa003216 – volume: 81 start-page: 1034 year: 1993 ident: e_1_3_3_8_2 publication-title: Obstet Gynecol – volume: 1 start-page: 111. year: 1963 ident: e_1_3_3_6_2 publication-title: Lancet – ident: e_1_3_3_10_2 doi: 10.1016/0010-7824(94)90106-6 – volume: 2 start-page: 1146 year: 1961 ident: e_1_3_3_7_2 publication-title: Lancet – ident: e_1_3_3_4_2 doi: 10.1001/jama.1975.03240190022010 – ident: e_1_3_3_13_2 doi: 10.1016/S0140-6736(95)91929-5 – volume: 351 start-page: 1404. year: 1998 ident: e_1_3_3_15_2 publication-title: Lancet – ident: e_1_3_3_27_2 doi: 10.1111/j.1471-0528.1998.tb10235.x – ident: e_1_3_3_16_2 doi: 10.1016/S0140-6736(95)12393-8 – ident: e_1_3_3_5_2 doi: 10.7326/0003-4819-89-1-58 – ident: e_1_3_3_26_2 doi: 10.1001/archneur.1995.00540280029015 – ident: e_1_3_3_21_2 doi: 10.1093/oxfordjournals.aje.a113955 – ident: e_1_3_3_22_2 doi: 10.1093/oxfordjournals.aje.a116946 – ident: e_1_3_3_19_2 doi: 10.1016/S0140-6736(99)01013-2 – ident: e_1_3_3_28_2 doi: 10.1056/NEJM199607043350102 – ident: e_1_3_3_25_2 doi: 10.1182/blood.V89.8.2817 – ident: e_1_3_3_1_2 doi: 10.1161/str.26.3.361 – ident: e_1_3_3_14_2 doi: 10.1136/bmj.312.7023.83 – volume: 2 start-page: 1191. year: 1962 ident: e_1_3_3_2_2 publication-title: BMJ – ident: e_1_3_3_12_2 doi: 10.1016/S0140-6736(95)91928-7 – ident: e_1_3_3_11_2 doi: 10.1016/S0140-6736(95)91926-0 |
SSID | ssj0002385 |
Score | 2.13677 |
Snippet | Background and Purpose
—
Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie,... Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie, those containing the... BACKGROUND AND PURPOSE: Epidemiological studies have shown an increased risk of venous thrombosis in women taking third-generation oral contraceptives, ie,... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1202 |
SubjectTerms | Adolescent Adult Arterial Occlusive Diseases - epidemiology Arterial Occlusive Diseases - etiology Biological and medical sciences Brain Ischemia - epidemiology Brain Ischemia - etiology Case-Control Studies Comorbidity Contraceptives, Oral - adverse effects Desogestrel - adverse effects Dose-Response Relationship, Drug Female Humans Levonorgestrel - adverse effects Medical sciences Middle Aged Netherlands - epidemiology Neurology Norpregnenes - adverse effects Odds Ratio Risk Assessment Risk Factors Stroke - epidemiology Stroke - etiology Surveys and Questionnaires Thrombosis - epidemiology Thrombosis - etiology Vascular diseases and vascular malformations of the nervous system |
Subtitle | Oral Contraceptives and the Risk of Ischemic Stroke |
Title | Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11988591 https://www.proquest.com/docview/197838839 https://www.proquest.com/docview/71643592 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1di9NAFB3qCiKI-G1dXefBB6Wkm0kmX75tZZdFreJuF_YtJJMZKLpJSVMffPPf-DO9d2aSNLCF1ZdQkmYCuSc3d07OPUPIm7iIilDlyolQ4cql7zm5CFwnhoQZc5WoWCHfMf8Snl7wj5fB5Wj0Z0u1tGnyqfh1bV_J_0QV9kFcsUv2HyLbDQo74DfEF7YQYdjeKMZnVhd-hLrMpe60r6urvEKTkWXZCd2wvvxaa5YAqVwtZPlp6FZNUSEzoG1mtadErR1DBn9sVZatDn0JU2Itql83dfV9ICY613u0_VMSuVs8wyeJFLltBZFZKZueiF1kpbE6mMmsp22xswqy4mRWrc16VXNjgTTBXvqO3p4h82FIJL3-9OTz5NiO3JIZXi8dnEqbgD3uYL_sdoY2VhkWicFWumWebte-5j0QMt3bMD1fnBmLSsjsPJhC8eLxqZFMbgFkdaURwlgSo59f_27sFIvtoVvkthdBlYaf_7_1vvRQ-ATW0hYufbj7wmhSa4caVEL3VtkaHkplVlPZPd3RZc_iAblv5yv0yIDvIRnJ8hG5M7eKjMfkN2KQVoq2GKQ9BumypC0GaVNRxCAdYpC-1Qh8RzX-3lNEHx2ijwL6KKCP1vZKLfqoQd8TcnFyvPhw6thlPRzhc7dxRCh44UmGaw-oHEpQ7uUsKAoBM_eEcxmFIvaLgiXCzZmIAxXg11sJKcSPC08o_ynZK6tSPie0kELyKEokzwOeKzeXBWfcLZRIMj_M3DFJ2lucCut5j0uv_Ej13DdkqctSiFTaRyrVkUr9kzHxu3NXxvnlRmcdDCLZn-qjc2fgj8l-G9rUppJ1ypCAjWGuMiavu6OQ5_HjHTyQ1WadIq_hB4k3Js8MHvqRLZ5e7DyyT-72D9tLstfUG_kKaukmP9Aw_gttcsDH |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+Arterial+Thrombosis+in+Relation+to+Oral+Contraceptives+%28RATIO%29+study%3A+oral+contraceptives+and+the+risk+of+ischemic+stroke&rft.jtitle=Stroke+%281970%29&rft.au=Kemmeren%2C+Jeanet+M&rft.au=Tanis%2C+Bea+C&rft.au=van+den+Bosch%2C+Maurice+A+A+J&rft.au=Bollen%2C+Edward+L+E+M&rft.date=2002-05-01&rft.eissn=1524-4628&rft.volume=33&rft.issue=5&rft.spage=1202&rft_id=info:doi/10.1161%2F01.STR.0000015345.61324.3F&rft_id=info%3Apmid%2F11988591&rft.externalDocID=11988591 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon |